MARKET

ASMB

ASMB

Assembly
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.700
-0.060
-3.41%
After Hours: 1.680 -0.02 -1.18% 19:14 01/21 EST
OPEN
1.760
PREV CLOSE
1.760
HIGH
1.760
LOW
1.670
VOLUME
981.24K
TURNOVER
--
52 WEEK HIGH
7.02
52 WEEK LOW
1.670
MARKET CAP
81.36M
P/E (TTM)
-0.6140
1D
5D
1M
3M
1Y
5Y
Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ...
Investment company Marquette Asset Management, LLC (Current Portfolio) buys Vanguard Total Bond Market ETF, ARK Next Generation Internet ETF, TAT Technologies, Avantis International Equity ETF, Dril-Quip Inc, sells Vanguard Short-Term Corporate Bond ETF, V...
GuruFocus.com · 3d ago
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced ...
GlobeNewswire · 01/07 22:00
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced ...
GlobeNewswire · 01/06 13:00
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today outlined anticipated progress and
Benzinga · 01/04 13:14
Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a poten...
Zacks · 12/07/2021 15:00
ASMB, BRKR and AVRO among after hour movers
Gainers: Assembly Biosciences (NASDAQ:ASMB) +11%. Bruker Corporation (NASDAQ:BRKR)+7%. AVROBIO (NASDAQ:AVRO) +6%. Sabre Corporation (NASDAQ:SABRP) +6%. Clover Health Investments (NASDAQ:CLOV) +5%. Losers: Selecta Biosciences (NASDAQ:SELB) -13%. Cyclerion T...
Seekingalpha · 11/26/2021 19:00
ASMB, FRLN and SABRP among after hour movers
Gainers: Assembly Biosciences (NASDAQ:ASMB) +9%. Freeline Therapeutics Holdings  (NASDAQ:FRLN) +6%. Sabre Corporation (NASDAQ:SABRP) +6%. InflaRx (NASDAQ:IFRX) +4%. Aurora Innovation (NASDAQ:AUR) +4%. Selecta Biosciences (NASDAQ:SELB) -21%. Cyclerion Thera...
Seekingalpha · 11/24/2021 22:00
BRIEF-Assembly Biosciences Presents Data Of HBV Core Inhibitor Portfolio At Liver Meeting
reuters.com · 11/12/2021 14:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASMB. Analyze the recent business situations of Assembly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
40.00%Buy
40.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ASMB stock price target is 10.00 with a high estimate of 15.00 and a low estimate of 2.500.
High15.00
Average10.00
Low2.500
Current 1.700
EPS
Actual
Estimate
-0.77-0.58-0.38-0.19
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 112
Institutional Holdings: 24.81M
% Owned: 51.84%
Shares Outstanding: 47.86M
TypeInstitutionsShares
Increased
25
1.09M
New
3
438.83K
Decreased
25
1.71M
Sold Out
29
4.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-1.11%
Key Executives
Non-Executive Chairman/Independent Director
William Ringo
President/Chief Executive Officer/Director
John McHutchison
Chief Financial Officer
Michael Samar
Chief Operating Officer
Jason Okazaki
Senior Vice President
Nicole White
Chief Scientific Officer
William Delaney
Other
Luisa Stamm
Director
Lisa Johnson-pratt
Independent Director
Anthony Altig
Independent Director
Gina Consylman
Independent Director
Richard DiMarchi
Independent Director
Myron Holubiak
Independent Director
Michael Houghton
Independent Director
Susan Mahony
No Data
About ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company advancing a class of oral therapeutic candidates for the treatment of chronic hepatitis B virus (HBV) infection. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H2158 (2158), and ABI-H3733 (3733). Vebicorvir (VBR) is licensed from Indiana University and treating patients with VBR plus nucelos(t)ide analog reverse transcriptase inhibitors (NrtIs) and ultimately transitioning patients. ABI-H2158 (2158) is chemically distinct from VBR. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company’s research and development programs pursuing multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.